MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • 2019 International Congress

    “UPDRS-meter” – a digital and automatic UPDRS scoring application

    Z. Yekutieli, S. Baer-Hassin, V. Livneh, T. Fay-Karmon, S. Israeli-Korn, G. Yahalom (Zichron Yaakov, Israel)

    Objective: To assess the feasibility of a smartphone-based application for performing a motor test that will provide an accurate UPDRS score. Background: Parkinson’s Disease (PD)…
  • 2019 International Congress

    A Case of Pregabalin induced Parkinsonism

    BC. Ari, F. Mayda Domac, G. Ozgen Kenangil (Istanbul, Turkey)

    Objective: Present a case of parkinsonism after administration of pregabalin, a rare case Background: Drug induced parkinsonism is the second common movement disorders after Parkinson’s…
  • 2019 International Congress

    Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease

    S. Rajput, S. Sinha (New Delhi, India)

    Objective: Objective of our study was to evaluate protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease. Background: Parkinson’s disease (PD),…
  • 2019 International Congress

    Drug-Induced Parkinsonism May Persist Beyond Two Years After Discontinuation of Dopamine Transmission Blocking Agents

    J. Randhawa, R. Mehanna (Houston, TX, USA)

    Objective: To demonstrate that patients with drug-induced parkinsonism (DIP) can remain symptomatic beyond 6 months, what majority of literature suggests, after withdrawal of causative agents.…
  • 2019 International Congress

    Re-emerging Neuroleptic Malignant Syndrome (NMS) without Re-introduced Neuroleptic in a Schizophrenia Patient: a Case Report

    D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

    Objective: To report a case with re-emerging neuroleptic malignant syndrome (NMS) without re-introduced neuroleptic drugs. Background: Neuroleptic Malignant Syndrome (NMS) is a potentially fatal idiosyncratic…
  • 2018 International Congress

    Effect of exercise on neurodegenerative parkinsonism unmasked by dopamine blocking drugs (DRBD)

    J. Morley, S. Wood, G. Cheng, K. Browne, K. Robinson, D. Weintraub, J. Duda (Philadelphia, PA, USA)

    Objective: To test whether aerobic walking influences clinical status, biochemical and radiologic markers associated with degenerative parkinsonism unmasked by DRBD. Background: Failed trials of putative…
  • 2018 International Congress

    Parkinson’s Disease Risk in Breast Cancer

    R. Mills-Joseph (Columbus, OH, USA)

    Objective: Case report of two patients who developed symptoms of Parkinson’s disease after treatment with chemotherapy and radiation for breast cancer and to review the…
  • 2018 International Congress

    Rotenone model of Parkinson’s disease: The dosing options in mice revisited

    M. Raza, N. Zehra, S. Malhi (Karachi, Pakistan)

    Objective: In the present study we have used various dosing protocols to induce the PD-like symptoms with the administration of rotenone in mice. Background: Parkinson's…
  • 2018 International Congress

    Diagnostic Impact of Movement Disorders Subspecialty Consultations at a VA Hospital

    B. Barton (Chicago, IL, USA)

    Objective: Review the impact of subspecialty care on diagnosis patterns of patients with parkinsonism at the Jesse Brown VA (JBVA), a VA Consortium center. Background:…
  • 2018 International Congress

    Salivary Alpha-Synuclein a new tool for the diagnosis of Parkinson’s disease?

    C. Aerts, C. Hirtz, V. Gonzalez, L. Collombier, M. De Verdal, C. Geny, M. Charif, E. Moulis, P. Fabbro-Peray, D. Deville Periere, P. Lapeyrie, G. Castelnovo, S. Lehmann (Nimes, France)

    Objective: The aim of the PARKSYN study was to test the utility of salivary alpha-synuclein (a-syn) concentration in the differential diagnosis between Parkinson's disease (PD)…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley